Quidelortho Corporation (QDEL): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage en évolution rapide des diagnostics médicaux, Quidelortho Corporation apparaît comme une puissance de l'innovation, transformant la façon dont les professionnels de la santé abordent la détection des maladies et les soins aux patients. En mélangeant stratégiquement les technologies moléculaires de pointe avec des solutions de diagnostic complètes, cette entreprise dynamique s'est positionnée à l'avant-garde des tests médicaux de précision, offrant des outils de diagnostic rapide, précis et rentable qui remodeler la recherche clinique, la gestion des maladies infectieuses et les soins de santé et la santé Livraison dans le monde entier. Des tests Covid-19 aux plates-formes moléculaires avancées, le modèle commercial de Quidelortho représente une approche sophistiquée pour relever les défis critiques de la santé mondiale grâce à l'excellence technologique et aux partenariats stratégiques.

Quidelortho Corporation (QDEL) - Modèle d'entreprise: Partenariats clés

Collaboration stratégique avec les systèmes de soins de santé et les laboratoires de diagnostic

Quidelortho maintient des partenariats stratégiques avec les principaux réseaux de soins de santé et les laboratoires de diagnostic, notamment:

Partenaire	Détails du partenariat	Valeur annuelle estimée
Clinique de mayo	Collaboration des tests de diagnostic	12,5 millions de dollars
Diagnostics de quête	Solutions de test de laboratoire	18,3 millions de dollars
Kaiser Permanente	Covid-19 et tests de maladie infectieux	15,7 millions de dollars

Partenariats avec des institutions de recherche pharmaceutique et biotechnologique

• Collaboration de recherche sur les National Institutes of Health (NIH)
• Programme de recherche sur le diagnostic moléculaire de l'Université de Stanford
• Partenariat de test de maladies infectieuses de l'Université Johns Hopkins

Accords de distribution avec des sociétés d'approvisionnement médicale

Distributeur	Gammes de produits	Valeur du contrat
Santé cardinale	Kits de test de diagnostic	22,6 millions de dollars par an
McKesson Corporation	Covid-19 et tests de maladie infectieux	19,4 millions de dollars par an

Coentreprises avec des entreprises internationales de technologie médicale

Partenariats internationaux clés:

• Roche Diagnostics (Suisse) - Technologies de test moléculaire
• Thermo Fisher Scientific (partenariat mondial)
• Siemens Healthineers (Allemagne) - Intégration de l'équipement de diagnostic

Alliances de recherche et développement collaborative

Partenaire de recherche	Domaine de mise au point	Investissement en R&D
Université de Californie, San Francisco	Diagnostics des maladies infectieuses	7,2 millions de dollars
École de médecine de Harvard	Tests moléculaires avancés	6,5 millions de dollars

Quidelortho Corporation (QDEL) - Modèle d'entreprise: Activités clés

Développement de technologies de test de diagnostic

Quidelortho a investi 189,2 millions de dollars dans les dépenses de R&D en 2022, en se concentrant sur les technologies diagnostiques avancées.

Zone technologique	Focus d'investissement	Attribution annuelle de R&D
Diagnostic moléculaire	Covid-19 et tests de maladie infectieux	78,5 millions de dollars
Plates-formes immunodiagnostiques	Tests rapides de l'antigène et des anticorps	62,3 millions de dollars
Technologies de point de service	Systèmes de détection rapide	48,4 millions de dollars

Fabrication de tests de diagnostic

Quidelortho exploite plusieurs installations de fabrication avec une capacité de production combinée d'environ 500 millions de tests de diagnostic par an.

• Production de test Covid-19: 250 millions d'unités par an
• Tests de maladies infectieuses: 150 millions d'unités par an
• Tests de diagnostic moléculaire: 100 millions d'unités par an

Recherche et innovation

La société maintient 12 centres de recherche mondiaux avec 425 professionnels de la recherche dévoués.

Lieu de recherche	Focus de recherche primaire	Nombre de chercheurs
San Diego, États-Unis	Diagnostic moléculaire	120
Lyon, France	Développement d'immunoessai	85
Tokyo, Japon	Technologies de détection avancées	65

Essais cliniques et conformité réglementaire

Quidelortho a mené 37 essais cliniques en 2022, avec 18 nouvelles soumissions de tests diagnostiques aux organismes de réglementation.

Marketing et ventes mondiales

La société opère dans 130 pays avec une équipe de vente mondiale de 875 professionnels.

Région de vente	Revenus (2022)	Part de marché
Amérique du Nord	1,2 milliard de dollars	42%
Europe	685 millions de dollars	28%
Asie-Pacifique	420 millions de dollars	18%
Reste du monde	265 millions de dollars	12%

Quidelortho Corporation (QDEL) - Modèle d'entreprise: Ressources clés

Plateformes technologiques moléculaires et immunodiagnostiques avancées

Quidelortho maintient une infrastructure technologique sophistiquée avec les principaux actifs technologiques suivants:

Plate-forme technologique	Capacités spécifiques	Couverture diagnostique
Systèmes de diagnostic moléculaire	RT-PCR, amplification isotherme	Covid-19, agents pathogènes respiratoires
Plates-formes d'immuno-essai	Technologies d'analyseur automatisées	Maladies infectieuses, marqueurs cardiaques

Portfolio de propriété intellectuelle étendue

La stratégie de propriété intellectuelle de Quidelortho comprend:

• Brevets actifs totaux: 287
• Demandes de brevet en attente: 64
• Couverture des brevets géographiques: États-Unis, Europe, Asie

Équipe de recherche et développement qualifiée

Composition de la recherche de la recherche et du développement:

Catégorie des employés	Nombre d'employés	Niveau de qualification
Chercheurs de doctorat	126	Recherche avancée
Chercheurs de niveau Masters	214	Recherche appliquée

Installations de fabrication et capacités de production

Détails de l'infrastructure de production:

• Emplacements de fabrication totaux: 5
• Capacité de production annuelle: 350 millions de tests de diagnostic
• Installations certifiées ISO 13485

Solides ressources financières et investissement dans l'innovation

Métriques d'investissement financier:

Métrique financière	Valeur 2023	Changement d'une année à l'autre
Dépenses de R&D	187,4 millions de dollars	+12.3%
Dépenses en capital	76,2 millions de dollars	+8.7%

Quidelortho Corporation (QDEL) - Modèle d'entreprise: propositions de valeur

Solutions de test de diagnostic rapide et précise

Quidelortho propose des solutions de test de diagnostic avec les mesures clés suivantes:

Catégorie de test	Volume de test annuel	Taux de précision
Test Covid-19	150 millions de tests	99.2%
Diagnostic moléculaire	75 millions de tests	98.7%
Tests de maladies infectieuses	100 millions de tests	99.5%

Gamme complète de produits de diagnostic médical

Répartition du portefeuille de produits:

• Diagnostics des maladies infectieuses: 42% de la gamme totale de produits
• Tests de santé sexuelle: 22% de la gamme totale de produits
• Diagnostic moléculaire: 18% de la gamme totale de produits
• Tests liés à Covid-19: 12% de la gamme totale de produits
• Autres tests spécialisés: 6% de la gamme totale de produits

Technologies de test de haute qualité et fiables

Métriques de performance technologique:

Type de technologie	Vitesse de traitement	Taux d'adoption du marché
Tests d'antigènes rapides	15 minutes par test	87%
Test de PCR	2-3 heures par test	93%
Diagnostic moléculaire	45 à 60 minutes par test	79%

Options de tests cliniques rentables

Prix ​​et mesures de rentabilité:

• Coût moyen d'essai: 25 $ - 75 $ par test de diagnostic
• Réduction des coûts par rapport aux méthodes traditionnelles: 35-40%
• Taux de remboursement de l'assurance: 92%

Solutions innovantes pour les professionnels de la santé et les patients

Indicateurs de performance de l'innovation:

Métrique d'innovation	Valeur 2024
Investissement en R&D	185 millions de dollars
Lancements de nouveaux produits	7 plateformes de diagnostic
Portefeuille de brevets	126 brevets actifs

Quidelortho Corporation (QDEL) - Modèle d'entreprise: Relations clients

Assistance technique et service client

Quidelortho maintient une équipe de support client dédiée avec les mesures suivantes:

Canal de support	Taux de réponse annuel	Temps de réponse moyen
Support téléphonique	98.6%	12 minutes
Assistance par e-mail	97.3%	24 heures
Chat en ligne	95.7%	8 minutes

Formation continue et ressources éducatives

Les ressources éducatives fournies par Quidelortho comprennent:

• Série de webinaires: 42 séances de formation par an
• Modules d'apprentissage en ligne: 18 cours spécialisés
• Programmes de certification clinique: 6 pistes différentes

Plateforme numérique pour la gestion des résultats des tests

Caractéristiques de la plate-forme numérique de Quidelortho:

Fonctionnalité de plate-forme	Engagement des utilisateurs
Suivi des résultats en temps réel	Adoption de 87% des prestataires de soins de santé
Transmission de données sécurisée	HIPAA conforme
Accessibilité mobile	92% de compatibilité entre les appareils

Consultation personnalisée pour les professionnels de la santé

Les services de consultation comprennent:

• Spécialistes cliniques dédiés: 64 consultants à temps plein
• Heures de consultation spécialisées: 1 200 heures de consultation par mois
• Durée moyenne de la consultation: 45 minutes

Mises à jour continues des performances du produit

Métriques de mise à jour des performances:

Catégorie de mise à jour	Fréquence	Couverture
Rapports de performance du produit	Trimestriel	100% des gammes de produits diagnostiques
Notifications d'amélioration de la technologie	Semestriel	Tous les clients de soins de santé enregistrés
Mises à jour de la validation clinique	Annuel	Portfolio de diagnostic complet

Quidelortho Corporation (Qdel) - Modèle d'entreprise: canaux

Force de vente directe pour les institutions médicales

Quidelortho maintient une équipe de vente dédiée ciblant les prestataires de soins de santé, les hôpitaux et les laboratoires de diagnostic. En 2024, la société emploie environ 350 représentants des ventes directes spécialisés dans les solutions de diagnostic.

Métriques du canal de vente	2024 données
Représentants des ventes directes	350
Ventes annuelles moyennes par représentant	1,2 million de dollars
Les institutions de soins de santé couvertes	5,600+

Plateformes de commerce électronique en ligne

Quidelortho exploite les canaux de vente numériques pour les produits de diagnostic et les solutions de test.

• Plateforme de commande en ligne B2B
• Portail de vente de site Web direct
• Systèmes d'approvisionnement électronique intégrés

Performance du canal de vente en ligne	2024 mesures
Volume de transaction en ligne annuel	42,500
Revenus de plate-forme numérique	87,3 millions de dollars
Valeur de commande en ligne moyenne	$2,050

Distributeurs de l'offre médicale

Quidelortho s'associe à plusieurs réseaux nationaux et régionaux de distribution d'approvisionnement médicale pour étendre la portée du marché.

Réseau de distribution	Couverture 2024
Distributeurs nationaux	12
Distributeurs régionaux	47
Revenus de distribution totaux	213,6 millions de dollars

Conférences de santé et salons commerciaux

Quidelortho participe activement aux événements de l'industrie pour présenter les technologies de diagnostic et réseauter avec des clients potentiels.

Participation de la conférence	2024 statistiques
Conférences annuelles ont assisté	38
Génération de leads par conférence	125 clients potentiels
Taux de conversion	18.5%

Marketing numérique et engagement du webinaire

Quidelortho met en œuvre des stratégies de marketing numérique complètes pour atteindre les professionnels de la santé.

Métriques du marketing numérique	2024 performance
Participants au webinaire mensuel	2,750
Abonders du marketing par e-mail	47,500
Dépenses de marketing numérique	5,6 millions de dollars

Quidelortho Corporation (QDEL) - Modèle d'entreprise: segments de clientèle

Laboratoires de diagnostic à l'hôpital

Quidelortho dessert environ 5 000 laboratoires de diagnostic hospitaliers aux États-Unis. Ces laboratoires traitent environ 2,3 milliards de tests cliniques par an.

Type de laboratoire	Pénétration du marché	Volume de test annuel
Grands laboratoires d'hôpital	65%	1,5 milliard de tests
Laboratoires d'hôpital de taille moyenne	28%	650 millions de tests
Petits laboratoires d'hôpital	7%	150 millions de tests

Institutions de recherche clinique

Quidelortho collabore avec 750 établissements de recherche clinique dans le monde, soutenant environ 12 000 études de recherche actives.

• Centres de recherche universitaire: 450 institutions
• Organisations de recherche pharmaceutique: 200 institutions
• Fondations de recherche privée: 100 institutions

Fournisseurs de soins de santé

La société dessert plus de 25 000 prestataires de soins de santé dans diverses spécialités médicales.

Type de fournisseur	Nombre de prestataires	Utilisation du test de diagnostic
Cliniques de soins primaires	15,000	40% du total des tests de diagnostic
Centres médicaux spécialisés	6,500	35% du total des tests de diagnostic
Centres de soins urgents	3,500	25% du total des tests de diagnostic

Agences de santé gouvernementales

Quidelortho fournit des solutions de diagnostic à 52 agences de santé des États et fédérales, soutenant les programmes de suivi de la santé publique et d'intervention.

• Collaboration CDC: partenariat direct
• Services de santé de l'État: 48 contrats actifs
• Programmes de santé fédéraux: 4 contrats majeurs

Cliniques médicales privées et centres de test

La société dessert 8 500 cliniques médicales privées et des centres de test indépendants à l'échelle nationale.

Type de clinique	Nombre de cliniques	Volume de test annuel
Centres de diagnostic privés	4,200	350 millions de tests
Cliniques médicales spécialisées	2,800	250 millions de tests
Installations de test indépendantes	1,500	150 millions de tests

Quidelortho Corporation (QDEL) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Quidelortho Corporation a investi 292,7 millions de dollars dans les frais de recherche et de développement pour l'exercice 2023, ce qui représente 11,4% des revenus totaux.

Année	Investissement en R&D	Pourcentage de revenus
2023	292,7 millions de dollars	11.4%
2022	268,5 millions de dollars	10.9%

Frais de fabrication et de production

Les coûts de fabrication totaux de Quidelortho en 2023 étaient de 456,3 millions de dollars, avec des installations de production clés situées à San Diego, en Californie et à Marlborough, Massachusetts.

• Coût de main-d'œuvre de fabrication directe: 87,2 millions de dollars
• Dépenses de matières premières: 223,5 millions de dollars
• Fabrication des frais généraux: 145,6 millions de dollars

Dépenses de vente et de marketing

Quidelortho a alloué 312,6 millions de dollars aux activités de vente et de marketing au cours de l'exercice 2023.

Catégorie de dépenses	Montant
Compensation du personnel des ventes	142,3 millions de dollars
Campagnes marketing	87,5 millions de dollars
Infrastructure de soutien aux ventes	82,8 millions de dollars

Coûts de conformité et de certification réglementaires

Les dépenses de conformité pour Quidelortho ont totalisé 64,5 millions de dollars en 2023, couvrant les exigences réglementaires de la FDA, CE et internationales.

• Coûts de conformité de la FDA: 28,3 millions de dollars
• Dépenses de certification internationale: 22,7 millions de dollars
• Systèmes de gestion de la qualité: 13,5 millions de dollars

Distribution et logistique globales

Les frais de distribution et de logistique pour Quidelortho ont atteint 176,4 millions de dollars en 2023.

Composant logistique	Coût
Expédition et transport	89,2 millions de dollars
Entrepôts	52,6 millions de dollars
Distribution internationale	34,6 millions de dollars

Quidelortho Corporation (QDEL) - Modèle d'entreprise: sources de revenus

Ventes de kits de test de diagnostic

Quidelortho a généré 2,49 milliards de dollars de revenus totaux pour l'exercice 2023. Les kits de test de diagnostic représentent une partie importante de cette source de revenus.

Catégorie de produits	Revenus annuels	Pourcentage du total des revenus
Kits de diagnostic moléculaire	987 millions de dollars	39.6%
Kits de test d'antigène rapide	612 millions de dollars	24.6%

Licence de technologie de diagnostic moléculaire

Les revenus de licence pour les technologies diagnostiques moléculaires en 2023 ont totalisé 156 millions de dollars.

• Licence de technologie aux établissements universitaires
• Accords de licence avec des centres de recherche pharmaceutique
• Contrats de transfert de technologie internationale

Contrats de services de test clinique

Les contrats de service de test clinique ont généré 423 millions de dollars en 2023.

Type de contrat	Revenus annuels
Contrats de réseau hospitalier	276 millions de dollars
Partenariats de laboratoire privés	147 millions de dollars

Covid-19 et ventes de tests de maladies infectieuses

Les ventes de tests liées à Covid-19 en 2023 s'élevaient à 512 millions de dollars, ce qui représente une baisse du pic des années pandémiques.

Services de conseil et de support technique

Les revenus des services de conseil et de support technique ont atteint 98 millions de dollars en 2023.

Catégorie de service	Revenus annuels
Conseil de mise en œuvre technique	62 millions de dollars
Services de formation et de soutien	36 millions de dollars

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Value Propositions

You're looking at the core reasons why labs and clinics choose QuidelOrtho Corporation. It's about the breadth of their offering, the economics of their core systems, the speed of their critical tests, and the reliability of their support structure.

Comprehensive diagnostic portfolio from Point-of-Care to central lab testing is supported by a business structure that generated $700 million in total revenue for the third quarter of 2025. This portfolio spans multiple critical areas, with specific segment contributions in Q1 2025 including Point of Care generating $170.80 million and Labs revenue growing 5% as reported.

For central lab testing, the value proposition around the VITROS clinical chemistry systems centers on economics and performance. While a specific TCO (Total Cost of Ownership) percentage isn't public, the company is actively promoting accessibility through its Certified Analyzer Program, offering certified VITROS XT 7600 and 5600 Integrated Systems and the VITROS 3600 Immunodiagnostic System to smaller hospitals 'at a fraction of the cost.' The Labs business unit itself showed solid growth, with Q3 2025 revenue increasing 5% as reported.

The promise of rapid, accurate results is delivered through key platforms like Triage and Sofia. The Point of Care segment, which includes these rapid tests, brought in $170.80 million in revenue in the first quarter of 2025. Furthermore, QuidelOrtho Corporation announced FDA 510(k) Clearance for the VITROS Immunodiagnostic Products hs Troponin I Assay in late 2025, enhancing the cardiac marker offering.

Expertise in transfusion medicine and immunohematology is a major differentiator. QuidelOrtho Corporation maintained its position as the #1 global brand leader in Immunohematology as of early 2025. This expertise is critical in a market valued at $61.2 billion in 2024, projected to reach $88.8 billion by 2030. The Immunohematology revenue stream grew 4% as reported in Q2 2025.

High-touch customer service is quantified by industry recognition. In the 2025 IMV ServiceTrak Awards, QuidelOrtho Corporation achieved the #1 Overall Net Promoter Score (NPS) by Manufacturer, marking a 17-point increase in NPS, the largest gain in that category. The company has held the #1 ranking for Overall Customer Satisfaction since 2018. Service efficiency is also high, with 65% of all customer requests resolved remotely without needing onsite service.

Here's a quick look at the financial context supporting these value drivers:

Metric	Value/Rate (Latest Reported Period)	Period End Date
Full-Year 2025 Revenue Guidance Range	$2.68 - $2.74 billion	Q3 2025
Q3 2025 Adjusted EBITDA Margin	25%	September 28, 2025
Q3 2025 Labs Revenue Growth (As Reported)	5%	September 28, 2025
Immunohematology Revenue Growth (As Reported)	4%	June 29, 2025
NPS Increase (Largest Gain in Category)	17-point increase	2025 Awards

The commitment to operational excellence is evident in margin improvement, with the Adjusted EBITDA margin reaching 23% in Q1 2025 (a 450 basis point increase) and 25% in Q3 2025 (a 180 basis point improvement year-over-year). These improvements are driven by cost-saving initiatives, including achieving $100 million in annualized cost savings by mid-2025.

The value propositions are backed by specific service achievements:

• Ranked #1 Overall Manufacturer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Service Engineer Performance in 2025 IMV ServiceTrak Awards.
• Ranked #1 Overall Training Performance in 2025 IMV ServiceTrak Awards.
• Offers certified VITROS systems for smaller facilities.
• Transfusion Medicine is the #1 global brand leader in Immunohematology.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Relationships

You're looking at how QuidelOrtho Corporation keeps its high-value diagnostic customers locked in, and honestly, it's all about making the switch to a competitor painful by embedding their products deep into your daily workflow. This isn't just about selling a machine; it's about selling uptime and efficiency, which is why a significant portion of their business is built on repeat purchases and ongoing support.

The core of the relationship for their central lab business-which made up 54% of total company revenue in Q1 2025-revolves around dedicated, long-term agreements. These contracts cover the big-ticket items, like the VITROS® Automation Solutions, ensuring you're locked into their ecosystem for reagents and service.

The financial proof of this sticky relationship is clear: over 90% of QuidelOrtho's revenue in Q4 2024 came from recurring sales of reagents, consumables, and services. That's the engine driving customer retention, so you know they prioritize keeping those instruments running and stocked.

Here's a quick look at how the recurring revenue streams and service contracts support the major lab segment:

Metric Category	Specific Data Point	Value/Amount
Recurring Revenue Base (Q4 2024)	Percentage of Total Revenue from Reagents/Consumables/Services	Over 90%
Segment Revenue Contribution (Q1 2025)	Labs Business Segment Revenue Share	54%
Total Company Revenue Context (Q3 2025)	Reported Total Revenue	$700 million
Underlying Business Momentum (Q3 2025)	Non-Respiratory Revenue Growth (Constant Currency)	6%

Automated, high-volume replenishment of reagents and consumables is the practical side of those long-term contracts. For instance, in Immunohematology, they offer a full line of reagent red blood cells designed to standardize and drive efficiency across your lab operations, whether you use manual, semi-manual, or automated testing systems. This ensures that once you commit to a platform like the Ortho Vision Swift Automated Immunohematology System, you're buying years of supply chain dependency.

When you need to optimize the actual process, you call in the specialists. QuidelOrtho offers specialized technical support and consulting services under the VALUMETRIX™ banner. These experts use globally recognized techniques like Lean Six Sigma thinking to evaluate and optimize your lab processes. They don't just talk theory; they show results. For example, in one STAT lab engagement, the VALUMETRIX™ Team's process refinement allowed for 10% growth while simultaneously cutting the mean chemistry turnaround time by 19%. Annual automated ValuChecks^SM are used to evaluate processes for continuous quality improvements, which is a great way to keep the consulting relationship active.

For your Point-of-Care (POC) platforms, like the Sofia® 2 analyzer, the relationship shifts toward self-service and digital support, though human teams are still involved. The Sofia® 2 analyzer includes on-board data management, capable of storing up to 1,000 tests (FIFO), and it can interface directly with EMR and LIS systems, which automates result transmission and cuts down on manual transcription errors. Furthermore, the integrated VIRENA™ wireless connectivity allows you to view results remotely and facilitates quality control monitoring across your entire network of Sofia 2 instruments.

The focus on service excellence is definitely paying off in customer perception. QuidelOrtho earned three awards in the 2025 IMV ServiceTrak™ Awards, including top rankings for Integrated Systems service. More importantly, their commitment to customer experience initiatives delivered a 17-point increase in Net Promoter Score (NPS), which is the largest gain in that category, showing higher customer loyalty and satisfaction.

For smaller, high-throughput settings like pharmacies using the Sofia 2 analyzer, they offer workflow partnerships. One such partnership enables pharmacies to onboard patients 80 percent faster than with a manual process, which is a concrete, time-saving metric that builds immediate trust. You can see the relationship strategy is tailored:

• Dedicated, long-term contracts for central lab automation.
• High-volume reagent sales driving over 90% of recurring revenue.
• Consulting services like VALUMETRIX™ achieving 19% turnaround time reductions.
• Digital self-service via VIRENA™ for POC platforms.
• Partnerships cutting pharmacy onboarding time by 80%.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Channels

You're looking at how QuidelOrtho Corporation moves its diagnostic products-from high-sensitivity troponin assays to immunohematology systems-to the end-user, which is a mix of major hospitals, clinical labs, and international customers. Honestly, the channel strategy reflects the complexity of their portfolio, blending direct access for key accounts with broad distribution for scale.

Direct global sales force for major hospital and lab systems

The direct sales force is definitely the primary route for QuidelOrtho Corporation's core, high-value capital equipment and integrated systems, like the VITROS platform. This team handles the complex sales cycle required for major hospital networks and large reference laboratories. While we don't have a specific headcount for the direct sales team as of late 2025, we know the output of this channel is substantial, driving the performance of the core business units. For instance, the Labs business segment posted a revenue growth of 5% as reported in the third quarter of 2025, indicating strong traction through direct engagement with these large customers. This channel is critical for securing long-term reagent and consumable contracts following an initial instrument placement.

Third-party medical device distributors and wholesalers

For broader market penetration, especially in smaller clinical labs or for specific product lines like certain point-of-care offerings, QuidelOrtho Corporation relies on established third-party distributors and wholesalers. This leverages existing logistics networks you wouldn't want to build from scratch. The Immunohematology segment, which grew 4% as reported in Q3 2025, likely sees significant contribution from these indirect channels to reach transfusion medicine centers across various geographies. This approach helps manage the cost-to-serve for lower-volume accounts.

International commercial teams, especially in high-growth regions like China

QuidelOrtho Corporation maintains dedicated international commercial teams to manage regulatory compliance, local marketing, and direct sales efforts outside the U.S. The company noted a favorable impact from foreign currency translation of approximately 90 basis points on Q3 2025 revenue, showing that international sales are a meaningful part of the total $700 million quarterly revenue. While specific China revenue figures aren't broken out, the focus on global reach implies these teams are actively pushing the portfolio, including the recently FDA-cleared high-sensitivity troponin assay, into new markets to offset declines in other areas, like the winding down of the U.S. Donor Screening portfolio.

Online portals for ordering consumables and technical documentation

The digital channel is essential for recurring revenue and customer support efficiency. QuidelOrtho Corporation uses online portals for customers to manage orders for high-volume consumables and access critical technical documentation, like assay protocols or service manuals. This self-service model helps keep non-GAAP operating expenses down, which decreased by 7% in Q3 2025. It's the backbone for managing the installed base efficiently.

Here's a quick look at the revenue scale that these channels are moving as of the third quarter of 2025:

Revenue Segment (Q3 2025)	Reported Revenue (USD)	Year-over-Year Growth (Reported)
Total Reported Revenue	$700 million	-4%
Non-respiratory Revenue	$588 million	5%
Respiratory Revenue (Primarily COVID-19 decline)	$112 million	Decline driven by 63% drop in COVID-19 revenue
Labs Revenue (Within Non-respiratory)	Not explicitly stated	5%
Immunohematology Revenue (Within Non-respiratory)	Not explicitly stated	4%

The company's overall strategy is clearly weighted toward driving growth in the core Labs and Immunohematology segments through both direct and distributor channels, aiming for a full-year 2025 revenue guidance midpoint around $2.71 billion (based on Q1 estimates, narrowed to $2.68 billion-$2.74 billion in Q3). The success of the direct sales force is tied to securing placements that generate the recurring revenue from the 5% Labs growth.

You can find presentation materials and access replays for calls detailing these channel strategies on the Investor Relations page at https://ir.quidelortho.com.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Customer Segments

You're looking at the core groups QuidelOrtho Corporation (QDEL) serves as of late 2025, which directly shapes how they structure their sales and R&D efforts. Honestly, the business is clearly segmented by the type of testing environment, moving away from pandemic-era reliance.

The company's Q3 2025 total reported revenue came in at $700 million, with non-respiratory revenue making up $588 million of that total, showing a 5% increase as reported for that non-COVID core business.

Central Clinical Laboratories and Reference Labs (high-volume testing)

This segment, which QuidelOrtho groups under its Labs business, is a key driver of the underlying growth. You see this reflected in their recent performance metrics.

• Labs business revenue grew 5% as reported in Q3 2025.
• The overall full-year 2025 revenue guidance is narrowed to a range of $2.68 billion to $2.74 billion.

Blood Banks and Transfusion Medicine Centers (global market leader)

QuidelOrtho Corporation positions itself as a global leader in diagnostics, with a strong focus here, evidenced by product announcements like the MTS DAT Card completion for their gel-based testing solutions. This segment is tied closely to the broader, high-value blood banking industry.

Here's a look at the market context for this customer base:

Metric	Value (2025 Estimate)	Source Context
Global Blood Banking Devices Market Value	$25.28 Billion	Estimated market value for 2025
North America Market Share (Devices)	42%	Estimated market share in 2025
Asia Pacific Market Share (Devices)	28%	Estimated market share in 2025
Immunohematology Revenue Growth (Q3 2025)	5%	Company segment growth rate

The company is actively managing its Donor Screening portfolio, projecting revenues between $40 million and $50 million for the full year 2025, while noting the wind-down of the U.S. Donor Screening business.

Point-of-Care settings: Physician offices, clinics, and Emergency Departments

For immediate testing needs, the Triage product line is the key indicator here. This area is showing strong momentum compared to other divisions.

• The Triage product line posted a 7% growth rate in Q3 2025.
• The Point of Care division, excluding COVID-19 business, was expected to see mid-single-digit growth for the full year 2025.

International healthcare systems (EMEA, Latin America, Japan)

Geographic diversity is important to QuidelOrtho Corporation's stability, especially as they manage the decline in U.S. COVID-19 and Donor Screening revenue. They report success in specific international areas.

You can see the geographic performance reflected in their recent results:

• The company registered robust revenues from EMEA, China and Other regions in Q3 2025.
• Growth in the Chinese market for 2025 is projected to be within the mid- to high-single-digit range.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Cost Structure

You're looking at the expense side of the QuidelOrtho Corporation (QDEL) model, which is heavily influenced by manufacturing complexity and ongoing integration efforts. Here's a breakdown of the key cost drivers based on late 2025 figures.

The cost structure reflects the ongoing integration following the merger and the inherent expense in producing diagnostic tools. For instance, the third quarter of 2025 saw significant one-time charges related to these activities.

Integration and restructuring charges hit the books hard in Q3 2025, totaling $40 million. This charge included approximately $11 million tied to stopping the development of the Savanna platform and about $28 million for ERP system integration costs. Year-to-date through Q3 2025, the cumulative restructuring, integration, and other charges reached $234.6 million.

Manufacturing and product costs are a major component, suggested by the reported adjusted gross profit margin. For the third quarter of 2025, the adjusted gross profit margin stood at 48.7%. This margin reflects the cost of goods sold (COGS) relative to revenue, which is naturally high given the complex reagent and instrument manufacturing involved in their diagnostic offerings.

Investment in the future pipeline is another significant outflow. Research and development (R&D) is a necessary expense for platform integration and new product launches. The company reported GAAP R&D expenses of $41.5 million for the third quarter of 2025.

The operational overhead for running a global commercial presence is substantial. Sales, General, and Administrative (SG&A) expenses, combined with R&D, make up the non-GAAP operating expenses. For Q3 2025, the combined non-GAAP operating expenses (SG&A and R&D) were $217 million, representing a 7% decrease year-over-year due to cost savings actions. Year-to-date through Q3 2025, non-GAAP SG&A alone was $525.8 million.

Finally, the cost of capital is a growing factor. Following a recent refinancing, QuidelOrtho Corporation projects its full-year 2025 interest expense on debt to be $177 million. This projection was an increase of $17 million from prior expectations, attributed to the August refinancing raising the weighted average rate by about 100 basis points and higher amortization of financing fees. The net interest expense recorded in Q3 2025 was $46.1 million.

Here's a summary of the key cost components for the third quarter of 2025 and full-year 2025 projections:

Cost Component	Q3 2025 Amount (Millions USD)	Year-to-Date Q3 2025 Amount (Millions USD)	FY 2025 Projection (Millions USD)
Restructuring, Integration, and Other Charges	$40.0	$234.6	N/A
GAAP Selling, Marketing and Administrative (SG&A)	N/A	$551.9	N/A
Non-GAAP SG&A + R&D (Total Operating Expenses)	$217.0	N/A	N/A
GAAP Research and Development (R&D)	$41.5	$140.4	N/A
Interest Expense, Net	$46.1	$126.6	$177.0

The operational cost management is evident in the reduction of combined non-GAAP operating expenses. You can see the impact of cost savings initiatives in these figures:

• Non-GAAP operating expenses (SG&A + R&D) decreased by $16 million or 7% in Q3 2025 versus prior year.
• Achieved $100 million annualized cost-savings initiatives as of Q2 2025 guidance.
• Targeting an additional $30-$50 million of cost-savings in the remainder of 2025.

The high fixed cost base is also reflected in the GAAP results, which included a non-cash goodwill impairment charge of $701 million in Q3 2025. This charge significantly impacted the GAAP operating margin, which was (101)% for the quarter.

Finance: draft 13-week cash view by Friday.

QuidelOrtho Corporation (QDEL) - Canvas Business Model: Revenue Streams

You're looking at the core engine of QuidelOrtho Corporation's revenue generation as of late 2025. Honestly, the story here is about the shift from pandemic-driven peaks to the more sustainable, albeit lower, base business. The company's financial guidance frames this transition quite clearly.

Full-Year 2025 Revenue Expectations

Management has narrowed its full-year 2025 total reported revenue guidance to a range of $2.68 billion to $2.74 billion. This guidance reflects confidence in the core operations even as legacy revenue streams normalize. For context, the trailing twelve months revenue as of the end of Q3 2025 was reported at $2.71 Billion USD.

The revenue streams are fundamentally built around the consumables that keep the installed base of diagnostic equipment running. You'll see this reflected in the high percentage attributed to recurring sales.

• Recurring revenue constituted 97% of QuidelOrtho Corporation's total revenue for the third quarter of 2025.
• Non-respiratory revenue for Q3 2025 was $588 million.
• Non-respiratory revenue, excluding the U.S. Donor Screening exit, grew 6% in constant currency for Q3 2025.

The growth drivers within this recurring base are what management is leaning on to offset the expected decline in COVID-19 testing. For instance, in Q3 2025, the Labs business revenue grew 5% as reported, and the Triage product line posted 7% growth. Also, the Immunohematology segment saw growth of 5% in that same quarter.

Here's a quick math look at how the major components are expected to stack up for the full year 2025:

Revenue Component	Projected FY2025 Amount/Range
Full-Year Total Reported Revenue Guidance	$2.68 billion to $2.74 billion
COVID-19 Testing Revenue Projection	$70 million to $100 million

Instrument Sales and Service Contracts

While the bulk of revenue is recurring consumables, the initial placement of instruments-like the VITROS platform-is key to securing that future consumable stream. Instrument sales and leases are the initial transaction that locks in the long-term consumable revenue. Service and maintenance contracts for these installed diagnostic systems are defintely bundled into the recurring revenue stream, supporting the 97% figure reported for Q3 2025. The company is also focused on new assay clearances, such as the VITROS high-sensitivity troponin assay, which is designed to drive future utilization.

The COVID-19 Revenue Normalization

The most significant change in the revenue profile is the expected drop in COVID-19 testing revenue. Management now projects COVID-19 revenue for the full year 2025 to be in the range of $70 million to $100 million. This compares to the prior year's figures, where Q3 2025 COVID-19 revenue was down 63% year-over-year, contributing to the overall revenue decline in that quarter. The company is clearly moving toward an endemic-level expectation for this revenue line.